Mainali Naba R, Bhatt Vijaya R, Kedia Shiksha, Krishnamurthy Jairam, Wake Laura M, Akhtari Mojtaba
Department of Medicine, Reading Health System, West Reading, PA, USA.
Division of Hematology and Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
J Oncol Pharm Pract. 2014 Oct;20(5):386-92. doi: 10.1177/1078155213504444. Epub 2013 Sep 24.
Interferon has been widely used in the management of patients with hematological malignancies such as polycythemia vera, myelofibrosis, chronic myeloid leukemia and viral infections such as chronic hepatitis C. Hematological adverse effects such as cytopenias have been observed, particularly in patients who receive a combination of interferon-α-2a and ribavirin for hepatitis C. Mild myelosuppression can be seen with pegylated interferon; however, bone marrow aplasia in patients with myelofibrosis has not been reported. It is important to be aware of such a serious complication since persistent bone marrow aplasia can be fatal. We describe a case of pegylated interferon-induced reversible bone marrow aplasia in a patient with primary myelofibrosis.
干扰素已广泛应用于血液系统恶性肿瘤患者的治疗，如真性红细胞增多症、骨髓纤维化、慢性髓性白血病，以及病毒感染如慢性丙型肝炎。已观察到血液学不良反应，如血细胞减少，尤其是在接受α-2a干扰素和利巴韦林联合治疗丙型肝炎的患者中。聚乙二醇化干扰素可导致轻度骨髓抑制；然而，尚未有骨髓纤维化患者发生骨髓再生障碍的报道。认识到这种严重并发症很重要，因为持续性骨髓再生障碍可能是致命的。我们报告一例原发性骨髓纤维化患者发生聚乙二醇化干扰素诱导的可逆性骨髓再生障碍的病例。
